CME: The recognition and diagnosis and management of anemia & hyperphosphatemia in CKD: Filtering it down to what the clinician needs to know
ACCREDITATION EXPIRED: January 04, 2024
Activity Description / Statement of Need:
In this online, self-learning activity:
Chronic kidney disease (CKD) affects about 15% of the general population in the United States and is the tenth-leading cause of death, accounting for 52,260 deaths in 2020. Along with the risk for end-stage kidney disease (ESKD) and cardiovascular disease (CVD), CKD has also been associated with a number of complications, including anemia and hyperphosphatemia. Anemia occurs in about 15% of patients with CKD and arises from decreased erythropoiesis and abnormal iron metabolism. Hyperphosphatemia occurs in the later stages of CKD because the kidney is the primary method by which the body maintains phosphate. This retention of phosphate leads to the development of CKD-mineral bone disorder (CKD-MBD), with the literature suggesting that hyperphosphatemia occurs in a large portion of patients on dialysis based on phosphate binder (PB) usage.
This learning activity has been designed to bring HCPs’ knowledge of the treatment and screening of anemia and hyperphosphatemia in patients with CKD up to date and to improve their competence and performance in treating it. It will walk participants through treatment pathways and review of the evidence behind therapies to treat CKD’s complications.
Target Audience:
The following HCPs: nephrologists and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in nephrology; and any other HCPs with an interest in or who clinically encounter patients with CKD.
Commercial Support Disclosure: This program is supported by educational grants from Akebia.
This activity is free of charge.
Release Date: January 04, 2022 -- Expiration Date: January 04, 2024
Faculty: Golriz Jafari, M.D.
Agenda
|
Epidemiology and pathophysiology of CKD anemia and hyperphosphatemia · Epidemiology o Prevalence and incidence o Risk factors · Pathophysiology o Erythropoiesis pathways o Iron metabolism o Phosphate retention |
|
Anemia of CKD · Diagnosis o Screening recommendations (ie, CBC, reticulocytes, ferritin, iron, TIBC, serum B12, folate, and occult blood) o Frequency of screening by presence of anemia and treatment type · Management o Setting hemoglobin targets o Transfusion o Iron deficiency treatment (oral vs intravenous iron) o Erythropoiesis-stimulating agents (when to initiate, selecting among options, approach to resistance) o Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors · Mechanisms of action · Study results · Potential use in clinic o Case study |
|
Hyperphosphatemia of CKD · Diagnosis o Screening recommendations (ie, calcium, phosphorous, and parathyroid hormone levels) o Frequency of screening · Management o Setting treatment targets o Non-calcium-based phosphate binders o Calcium-based phosphate binders o Sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor o Mechanisms of action o Study results o Potential use in clinic · Case study |
Learning Objectives
By the end of the session the participant will be able to:
- Discuss the prevalence of common CKD complications and the burden they place on patients.
- Recall recommendations for effectively monitoring for anemia and hyperphosphatemia in patients with CKD.
- Formulate a treatment plan for patients with anemia or hyperphosphatemia of CKD.
- Describe the mechanisms of action and potential impact of emerging agents with novel mechanisms of action for the treatment of CKD anemia and hyperphosphatemia.
Accreditation
ACCME Activity #201809247
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure:
Golriz Jafari, MD, Associate Clinical Professor, UCLA School of Medicine, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by educational grants from Akebia.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty will not discuss off-label uses of a commercial product.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Alpha-1 antitrypsin deficiency (AATD): Optimizing pharmacotherapeutic management strategies
Hemophilia B: Optimizing Pharmacotherapeutic Management Strategies